News Agency
Men's Weekly

First participant treated at the highest dose level in Clarity's theranostic prostate cancer trial

  • Written by PR Newswire
First participant treated at the highest dose level in Clarity's theranostic prostate cancer trial

Highlights

  • First participant of cohort 3 in the theranostic SECuRE trial investigating 64Cu/67Cu SAR-bisPSMA in metastatic castrate-resistant prostate cancer (mCRPC) has been treated at the highest dose level of 12GBq.
  • Cohort 2 was recently completed in 3 participants who received therapy with 67Cu SAR-bisPSMA at the dose level of 8GBq.
  • Data from...

Read more: First participant treated at the highest dose level in Clarity's theranostic prostate cancer trial

How Often Should You Visit the Dentist? Here’s What Experts Say

When it comes to having a healthy smile, perhaps the most frequently asked question is, "How frequently should I go to the dentist?" Although there's a rule of thumb that says visit the dentist every six months, the truth isn't... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion